On 11 June 2024, Alvotech announced that it has expanded its current partnership with STADA to include AVT03 (denosumab), biosimilar to Amgen’s Prolia®/Xgeva®.
Under the agreement, STADA will be the sponsor of the Alvotech developed product, with semi-exclusive rights to commercialise AVT03 in Europe, Switzerland and the UK and exclusive rights in certain Central Asian and Middle Eastern countries.
The companies’ November 2019 strategic partnership already covers:
- Hukyndra® (AVT02), a high concentration biosimilar to AbbVie’s Humira® (adalimumab), first launched in Europe in June 2022 and in Switzerland in September 2022; and
- Uzprovo® (AVT04), biosimilar to Janssen’s Stelara® (ustekinumab), EU-approved in January 2024 and expected to launch following the expiry of Stelara’s SPC in July 2024.
Under the June 2024 agreement, STADA’s commercialisation rights to the adalimumab and ustekinumab biosimilars will be extended to Commonwealth of Independent States (CIS). Alvotech will regain commercial rights from STADA to AVT06, biosimilar to Regeneron’s Eylea (aflibercept), for which positive top-line results were reported in January 2024.